|Bid||0.00 x 1000|
|Ask||0.00 x 1000|
|Day's Range||152.75 - 155.45|
|52 Week Range||105.56 - 175.91|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||21.97|
|Earnings Date||Jul 28, 2022 - Aug 01, 2022|
|Forward Dividend & Yield||5.64 (4.08%)|
|Ex-Dividend Date||Apr 14, 2022|
|1y Target Est||163.01|
In the latest trading session, AbbVie (ABBV) closed at $153.14, marking a +0.53% move from the previous day.
The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.
AbbVie recently applied for FDA approval of its advanced Parkinson's disease drug candidate. This could be huge considering it's set to lose market exclusivity of Humira.